ArticleThe Lancet regional health. Europe2025
Impact of a national HPV vaccination programme for preadolescent girls on cytology screening performance and CIN2+ incidence: five-year population-based cervical screening results from Slovenia.
Article in The Lancet regional health. Europe, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- HPV Vaccine: An Effective but Underutilized Prevention Tool.International journal of environmental research and public health · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: HPV vaccination is most efficacious in preventing cervical cancer and its precursors when administered during preadolescence. Because in Slovenia women are invited for cytology screening from age 20, women targeted for preadolescent HPV vaccination have been screening-eligible since 2018. We aim to assess the impact of preadolescent HPV vaccination programme on cytology screening performance and CIN2+ incidence. Methods: This is a cohort study using data from Slovenia's cervical screening registry. We compared the incidence of high-grade lesions (CIN2 or worse) between women in the first vaccine-targeted birth cohort (1998-2001) and in the latest non-vaccine-targeted birth cohort (1994-1997). We calculated the Incidence Rate Ratio (IRR) of CIN2+ using Poisson regression. To identify a possible shift in the harms-benefits ratio of screening, we compared the following screening performance indicators using chi-square tests: colposcopy referral rate (CRR), positive predictive value (PPV) of low-grade and high-grade results, and CIN2+ detection rate. Findings: The annual quadrivalent vaccine coverage in vaccine-targeted cohort was between 48.7% and 55.2%. The CIN2+ incidence was substantially lower in vaccine-targeted cohort (IRR 0.58 95% CI 0.49-0.69). Screening indicators were significantly lower for the vaccine-targeted cohort: direct CRR (0.47% [118/25,185] vs. 0.68% [206/30,181]), PPV (26.8% [30/112] vs. 39.0% [76/195]), and CIN2+ detection rate (0.31% [79/25,185] vs. 0.55% [165/30,181]) (p < 0.05). Interpretation: Even under imperfect vaccination coverage of around 50%, CIN2+ incidence in the vaccine-targeted cohort was observed to be 42% lower. Furthermore, the harms-benefits ratio of cervical screening deteriorates, marked by lower PPV and detection rate. This warrants an adaptation in screening algorithms in vaccinated cohorts. Funding: European Union Horizon 2020.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.